Source: Eur Respir J, 52 (5) 1801393; 10.1183/13993003.01393-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner, Xiao Xu. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J, 52 (5) 1801393; 10.1183/13993003.01393-2018

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 The association between adherence and outcomes in severe asthma: a systematic review Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019 As needed therapies in mild to severe asthma: a systematic review and network meta-analysis Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma Source: ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021 Year: 2021 The burden of exacerbations in mild asthma: a systematic review Source: ERJ Open Res, 6 (3) 00359-2019; 10.1183/23120541.00359-2019 Year: 2020 Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials Source: International Congress 2017 – COPD management Year: 2017 Subcutaneous anti-immunoglobulin E (Omalizumab) as a steroid-sparing agent in allergic asthma – a systematic review of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients. Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Deprescribing montelukast in children with asthma: a systematic review Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021